Skip to main content

GVK Extends Database License to FDA

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – GVK Biosciences today said that it has extended its license for its Clinical Biomarker Database to the US Food and Drug Administration.

The extension is for a license, originally forged in 2007, to the database with FDA's Biomarker Qualification Group.

Financial and other terms of the extension were not disclosed.

The database called GoBiom is a collection of all clinically evaluated exploratory and preclinical biomarkers that are associated with different therapeutic areas reported in global clinical trials, and clinical and preclinical studies, GVK said. It contains data on 12,000 biochemical, genomic, imaging, metabolite, cellular, and physiological biomarkers with multiple data points covering experimental, analytical, clinical, and statistical data.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.